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Abstract
Background: Hyperemesis gravidarum (HG), or intractable vomiting during pregnancy, is the single most
frequent cause of hospital admission in early pregnancy. HG has a major impact on maternal quality of life
and has repeatedly been associated with poor pregnancy outcome such as low birth weight. Currently,
women with HG are admitted to hospital for intravenous fluid replacement, without receiving specific
nutritional attention. Nasogastric tube feeding is sometimes used as last resort treatment. At present no
randomised trials on dietary or rehydration interventions have been performed. Small observational studies
indicate that enteral tube feeding may have the ability to effectively treat dehydration and malnutrition and
alleviate nausea and vomiting symptoms. We aim to evaluate the effectiveness of early enteral tube feeding
in addition to standard care on nausea and vomiting symptoms and pregnancy outcomes in HG patients.
Methods/Design: The MOTHER trial is a multicentre open label randomised controlled trial (www.studies-obsgyn.nl/
mother). Women≥ 18 years hospitalised for HG between 5 + 0 and 19 + 6 weeks gestation are eligible for participation.
After informed consent participants are randomly allocated to standard care with intravenous rehydration or early
enteral tube feeding in addition to standard care. All women keep a weekly diary to record symptoms and dietary
intake until 20 weeks gestation. The primary outcome will be neonatal birth weight. Secondary outcomes will be the
24-h Pregnancy Unique Quantification of Emesis and nausea score (PUQE-24), maternal weight gain, dietary intake,
duration of hospital stay, number of readmissions, quality of life and side-effects. Also gestational age at birth, placental
weight, umbilical cord plasma lipid concentration and neonatal morbidity will be evaluated. Analysis will be according
to the intention to treat principle.
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Discussion: With this trial we aim to clarify whether early enteral tube feeding is more effective in treating HG than
intravenous rehydration alone and improves pregnancy outcome.
Trial registration: Trial registration number: NTR4197. Date of registration: October 2nd 2013.
Keywords: Hyperemesis, Nausea and vomiting in pregnancy, Tube feeding, Intravenous rehydration, Effectiveness, Outcomes
Background
Nausea and vomiting in pregnancy (NVP) is common, af-
fecting 50–80 % of pregnancies [1]. Often these symptoms
are mild and self-limiting and resolve without intervention
in the second trimester. In other cases however, severe in-
tractable vomiting can lead to dehydration, electrolyte dis-
turbances and significant weight loss necessitating
hospital admission. The condition of intractable vomiting
during pregnancy is called hyperemesis gravidarum
(HG) [2]. HG has repeatedly been associated with
poor pregnancy outcome including low birth weight
(LBW, <2500 g: OR 1.42), small for gestational age
(OR 1.28) and prematurity (OR 1.32) [2–4]. Furthermore,
HG has a major impact on maternal wellbeing and quality
of life [5–7] and remains the largest single cause of hos-
pital admission in early pregnancy [8, 9]. However, the
aetiology of HG is poorly understood [10–12].
Approximately 0.8–2 % of all pregnancies are compli-
cated by HG [2]. Currently, there are no treatments with
proven efficacy available according to the latest Cochrane
review on interventions for nausea and vomiting in early
pregnancy [1]. Hospitalisation can be required for intraven-
ous treatment of dehydration and electrolyte imbalance.
Currently, women who suffer from HG do not receive any
particular nutritional attention, although enteral tube feed-
ing is sometimes used as a treatment of last resort [2, 13].
Enteral tube feeding effectively treats both dehydration and
malnutrition in non-pregnant patients with poor intake
[14] and has been shown to be safer than parenteral nu-
trition in pregnancy [15]. Moreover, in several small
studies in women with HG, which did not employ a
control group, it alleviated symptoms and was well
tolerated if continued in a home setting [16–18].
There have been no controlled trials to investigate
the extent to which enteral tube feeding can positively
affect pregnancy outcome and maternal quality of life,
nausea and vomiting symptoms or time in hospital.
At present, there is no evidence on the effectiveness
and efficiency of rehydration and dietary interventions
for HG. We hypothesise that enteral tube feeding in
addition to standard care is a more effective treatment
for HG symptoms than standard care with intravenous
rehydration alone, and improves pregnancy outcome.
This multicentre randomised controlled trial (RCT) aims
to compare early enteral tube feeding in addition to
standard care, with standard care alone. Outcomes of inter-
est are birth weight and maternal nausea and vomiting
symptoms, maternal quality of life, duration of hospitalisa-
tion, weight gain and neonatal morbidity. The study is
conducted within the Dutch Consortium for Studies in Ob-
stetrics, Fertility and Gynaecology (www.studies-obsgyn.nl).
Methods/Design
Participants/ eligibility criteria
Patients ≥ 18 years of age are eligible if they have been
admitted to hospital because of HG (first admission or
readmission) at a gestational age between 5 + 0 and 19 +
6 weeks. Patients with singleton or multiple pregnancies
are eligible. A diagnosis of HG is made if excessive
nausea or vomiting necessitates hospital admission, in
the absence of any other obvious cause such as drug
induced vomiting or infection.
Exclusion criteria are mola hydatidosa pregnancy,
non-vital pregnancy, acute infection causing vomiting
(e.g. appendicitis, pyelonephritis), contraindication for
enteral tube feeding (e.g. oesophageal varices, allergies
to enteral tube mix compounds) or HIV infection.
Procedures, recruitment and randomisation
This study is a nationwide multicentre open label RCT
conducted within the Dutch Consortium for Studies in
Obstetrics, Fertility and Gynaecology, a nationwide col-
laboration of hospitals in the Netherlands. The staff and/
or local research coordinator of the participating hospi-
tals identifies eligible women. After counselling and
reading the patient information form, patients are asked
for written informed consent. Patient information is pro-
vided in Dutch and English. See Fig. 1.
Randomisation is performed by a web based compu-
terised program using permuted-block randomisation.
Randomisation is allocated in a 1:1 ratio for standard
care or enteral tube feeding in addition to standard care,
with a block size of four. Stratification according to
centre is applied.
Intervention
Participants are allocated to standard care or enteral tube
feeding in addition to standard care. Standard care con-
sists of intravenous rehydration and, when considered ne-
cessary, laboratory monitoring, electrolyte and/or vitamin
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supplementation, antiemetic medication and dietetic ad-
vice. Type of rehydration regimen, medication and dur-
ation of hospitalisation is prescribed according to local
protocol. In case of prolonged hospital admission or read-
missions, tube feeding can be initiated at the decision of
the attending physician.
Fig. 1 CONSORT 2010 flow diagram MOTHER trial
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When allocated to the intervention group, participants
receive a nasogastric tube as soon as possible after ran-
domisation, in addition to standard care. If the initial
nasogastric tube is dislocated or poorly tolerated a naso-
duodenal or nasojejunal insertion can also be consid-
ered. Tube feeding regimen and mix is prescribed
according to local protocol. As soon as tube feeding is
tolerated and participants have received safety instruc-
tions (e.g. recognising symptoms that need to be evalu-
ated in hospital, because of potential tube blockage,
dislocation or aspiration), discharge home with tube
feeding is encouraged under the guidance of a hospital
dietician. Energy intake per tube is continued at least
until the patient is able to maintain an oral intake of
1000 cal per day for one week. According to the NICE
guideline on nutrition, tube feeding in a home setting is
considered to be safe [14].
Data collection
At the day of randomisation, participants fill out a ques-
tionnaire. This questionnaire consists of validated NVP
symptom and NVP specific quality of life measures
(24-h Pregnancy Unique Quantification of Emesis and
nausea score, PUQE-24; Hyperemesis Impact of Symp-
toms questionnaire, HIS; Nausea and Vomiting in Preg-
nancy Quality of Life questionnaire, NVPQoL) [7, 19–21],
psychopathology (Hospital Anxiety and Depression Scale,
HADS; Symptoms CheckList 90, SCL-90) [22–25] and
general health related questions (Short Form 36, SF-36;
EuroQol 5 Dimensions questionnaire,EQ5D) [26, 27].
Participants fill out additional questionnaires (NVPQoL,
HIS, HADS) 1 and 3 weeks after randomisation and rec-
ord a diary at weekly intervals (PUQE-24, weight, medica-
tion use, dietary intake) from randomisation until
20 weeks gestation. If dietary intake has normalised from
15 weeks gestation onwards, this is no longer recorded.
Six weeks postpartum (HADS, SF-36, EQ5D) and
12 months postpartum a final questionnaire is filled out
(HADS, SF-36, EQ5D, SCL-90). See Table 1.
To evaluate potential HG and birth weight predictors,
detailed information on obstetric and medical history,
anthropometrics (before and during pregnancy), anti-
emetic medication use, given treatment(s) (including
intravenous and/or tube feeding regimen and tube loca-
tion), laboratory results, treatment and pregnancy com-
plications and birth outcomes are collected using a
standardised Case Report Form (CRF; see Additional
file 1). Research staff obtains the information needed
based on medical and dietician records. Maternal demo-
graphics (ethnicity, education level, marital status), mode
of conception and onset of nausea and vomiting symp-
toms are enquired via the questionnaire.
All participants in this trial are asked for informed
consent of storage of maternal blood (taken with routine
laboratory analysis during hospital admission for HG),
cord blood and placental biopsies (taken at birth) in an ob-
stetrical biobank (the Preeclampsia and Non-preeclampsia
Database, Academic Medical Centre Amsterdam, the
Netherlands). The addition of these samples will enable
molecular studies in HG aetiology and consequences. Fur-
thermore, cord blood will be used for the assessment of
plasma lipids (cholesterol, HDL, LDL, triglycerides, Apoli-
poprotein A and B), glucose, leptin and thyroid function
(TSH, fT4).
Outcome measures
Primary outcome measure
The primary outcome will be neonatal birth weight.
Secondary outcome measures
Secondary outcomes will be the validated PUQE-24
score one week after randomisation, maternal weight
gain, dietary intake, HIS, NVPQoL, EQ5D, SF-36, HADS
and SCL-90 scores, urinary ketones, duration of hospital
stay and number of readmissions. Furthermore, gesta-
tional age at birth, preterm birth rate, small for gestational
age (SGA; <10th percentile) placental weight, umbilical
cord plasma lipids, neonatal hypoglycaemia, hyperbilirubi-
naemia and congenital anomalies will be evaluated. Lastly,
we will evaluate maternal side effects of tube feeding and
intravenous rehydration and reasons for discontinuation
of the allocated treatment.
Follow-up of infants
A plan for long-term follow up of children is in prepar-
ation, because little is known about the long term health
effects of babies born to mothers whose pregnancies were
complicated by HG and we have reason to hypothesise
that maternal malnutrition during early pregnancy has
long term effects on the offspring’s cardiometabolic health
[4]. Funding for follow-up has not yet been obtained.
Statistical issues
Sample size
The sample size is based on a difference in mean birth
weight of 200 g (SD 400 g) between the intervention
group and the control group, which we consider clinically
relevant. With a beta of 0.2 and alpha of 0.05 and a pos-
sible 10 % loss to follow up, we need to randomise 120
participants (60 per arm). This sample size is also large
enough to detect a two point reduction in PUQE-24 score
1 week after randomisation (maximum 15 points, SD 3
points) and differences in quality of life, psychopathology
and general health questionnaires ≥ 10 %.
Data analysis
Data will be analysed according to the intention to
treat principle. Difference in birth weight will be
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assessed using parametric testing. PUQE-24 score will
be analysed using multivariate regression and repeated
measurements ANOVA or mixed models, as will be
quality of life assessments. Other secondary outcomes
will be addressed in a similar manner. For non-
normally distributed variables non-parametric equiva-
lents will be used. To evaluate the potential of each
of the strategies, we will also perform a per protocol
analysis, taking into account only those women that
were treated according to protocol.
Data safety monitoring committee
Serious Adverse Events (SAEs) are reported to the
Data Safety Monitoring Committee (DSMC). The
DSMC can decide, if indicated, to terminate the trial
prematurely.
Ethical considerations
This trial has been approved by the ethics committee of
the Academic Medical Centre Amsterdam (Reference
number MEC AMC 2012_320) and by the boards of
management of all participating hospitals. The trial is
registered in the Dutch Trial Register, NTR4197, http://
www.trialregister.nl webcite. Date of registration: October
2nd 2013. The full protocol can also be downloaded from
the study website: www.studies-obsgyn.nl/mother.
Discussion
Since HG is the largest cause of hospital admission in
early pregnancy and has major consequences for ma-
ternal quality of life, with possible adverse effects on
birth outcomes, evidence based treatment options are
needed. Optimal treatment should be safe, reduce ma-
ternal complaints, duration of hospital stay and min-
imise adverse effects on offspring health. This trial
will provide evidence on these subjects comparing
standard care with intravenous rehydration and early
enteral tube feeding in addition to standard care.
Additional files
Additional file 1: Case Report Form MOTHER trial. (PDF 252 kb)
Additional file 2: CONSORT 2010 checklist MOTHER trial. (DOCX 48 kb)
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Table 1 Time line MOTHER trial
T0 T1 T2 T3 T4 T5 T6 T7
Randomisation +1 week + 2 weeks + 3 weeks + 4 weeks until GA
20 weeks
Birth 6 weeks post-
partum
12 months post-
partum
Diary
PUQE X X X X X
Current weight X X X X X
Medication use X X X X X
Dietary intake X X X X Xa
Questionnaires
General health X
NVPQoL X X X
HIS X X X
HADS X X X X X
SF-36 X X X
EQ5D X X X
SCL-90 X X
Biobank material
Maternal blood X
Cord blood X
Placental
biopsies
X
PUQE pregnancy unique quantification of emesis and nausea score, NVPQoL nausea and vomiting in pregnancy quality of life questionnaire, HIS hyperemesis impact of
symptoms questionnaire, HADS hospital anxiety and depression scale, SF-36 short form 36, EQ5D euroQol 5 dimensions questionnaire, SCL-90 symptoms checklist 90
aIf dietary intake has normalised from GA 15 weeks onwards, this will be no longer recorded
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